Outspoken drug pricing researcher Peter Bach takes CMO gig at liquid biopsy startup
After spending more than a decade criticizing the industry over drug pricing, Memorial Sloan Kettering’s outspoken researcher Peter Bach is jumping over to the C-suite of a liquid biopsy startup.
Bach, known for his frank tweets and frequent editorials, is taking the CMO role at Delfi Diagnostics, a Baltimore-based biotech that’s looking for a better way to screen the blood for cancer. The company snagged $100 million at the beginning of the year, and a couple months ago initiated a national trial for lung cancer screening.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.